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Introduction
During the development of cardiac hypertrophy, heart failure, and ischemia reperfusion
challenge, the heart accumulates misfolded proteins as a result of cellular stresses 1–4. While
the compensatory increases in chaperones/co-chaperones work to prevent misfolding, refold
denatured proteins and/or target them for degradation, this system can become
overwhelmed, leading to worsening of cardiac function. In fact, recent studies have
demonstrated experimentally that increasing the burden of misfolded proteins in the heart
can contribute to the development of cardiac dysfunction 5. In this review, we discuss the
role of heat shock proteins in common cardiac diseases including cardiac hypertrophy, heart
failure, and ischemia/reperfusion injury. Furthermore, we delineate the many specific
mechanisms by which these chaperones, co-chaperones, and heat shock factor (HSF)
transcription factors have been found to be cardioprotective in experimental models. Lastly,
we review recent studies involving drugs that are being developed (and currently used) to
increase the expression (and presumably function) of chaperone/co-chaperone systems that
may be applicable to the treatment of common cardiac diseases as well as familial cardiac
diseases whose etiology includes a major component of misfolded proteins (e.g.
desminopathies).
Chaperones enhance productive protein folding and refolding and prevent
protein aggregation
There are several general families of molecular chaperones in the cytoplasm of mammalian
cells, including heat shock protein (HSP) 90, HSP70, CCT (also called TRiC), and small
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HSP (sHSP) family proteins (Figure 1A). Members of the HSP90 family of chaperones are
the most abundant chaperones located in the cytosol. They form dimers consisting of
HSP90α and HSP90β subunits and are inducible with stress, although are quite abundant
without stress also 8, 9. HSP90 assists many proteins involved with signal transduction,
including more than 40 kinases and many steroid hormone receptors, with a supporting role
in conformational changes involved in ATP hydrolysis 10, 11. The HSP70 chaperone family
consists of 6 member proteins that are found in the cytosol 12, including HSP70 and the
cognate of HSP70 (HSC70). Like HSP90, HSP70 proteins are inducible with stress,
however they are also highly abundant without stress. HSP70 family members are
functionally highly homologous, recognizing hydrophobic surfaces of unfolded proteins and
partially folded intermediates. Their activity is controlled by their hydrolysis activity as well
as by their ability to bind ATP 13. HSP90 and HSP70 proteins both inhibit protein
aggregation, thereby promoting productive folding of proteins (for comprehensive reviews,
see Young et al.14–16).
Other molecular chaperones present in the cytosol include TRiC (TCP1-ring complex, or
chaperonin containing TCP1 (CCT)) 17, 18. The central cavity of TRiC uses a lid-like
structure to encapsulate substrate proteins to allow it to trap and fold target proteins. This
encapsulation prevents aggregation and allows changes in conformation that ensure correct
folding (in an ATP-dependent manner) before substrates are released. The family of sHSPs
also maintain protein confirmation in an ATP-independent manner 19. Over 10 sHSP
chaperone proteins have been characterized and all function by maintaining an equilibrium
between the dimer and large oligomer states of their target proteins 20. In contrast to HSP90
and 70 though, only a few sHSPs (including HSP27, HSP22, and alphaB-crystallin) are
increased in response to stress 21. HSP27 and alphaB-crystallin (CryAB) are abundant in
cardiac and skeletal muscles and increase in response to stress in order to protect against
insults such as ischemia 22. Both these proteins associate with actin and are vital to muscle
development and assembly 23. CryAB also interacts with several other cytoskeletal proteins
such as desmin to maintain protein folding and prevent aggregation 24–27.
In addition to the molecular chaperones that are found predominantly in the cytosol, there
are also chaperones that are known to maintain proteins in other compartments of the cell, in
particular the mitochondria. HSP60 is a chaperone originally identified in the mitochondria
28 but which is also found in the cytosol 29. HSP60 is responsible for refolding and
transportation of proteins between the mitochondrial matrix and the cytoplasm of the cell 30
and associates with a number of cytosolic proteins involved in apoptosis such as B-cell
lympohoma-1-assocated X protein (BAX), B-cell lymphoma (BCL)-xl and BCL-2
homologous antagonist/killer (BAK) 31, 32. HSP60 is believed to be a homolog of the
bacterial heat shock protein groEL and, as such, it is believed that HSP60 assists in folding
linear amino acids into their three dimensional structures in ways that have been described
for groEL 33.
Co-chaperones control the activity of chaperones: DnaJ, BAGs, Hop, CHIP,
Immunophilins, and Prefoldin
As their name implies, co-chaperones are proteins that assist chaperone functions, including
in protein folding. There are over 40 genes in the HSP40/DnaJ protein family, with the
different members playing diverse roles in regulating protein folding, assembly,
translocation, and even degradation. DnaJ proteins bind to the ATPase binding domain of
HSP70 proteins to enhance their ATPase activity 34. They also bind substrate proteins to
modulate folding in a substrate-specific manner. Bcl2-associated athanogene (BAG)
proteins all have a conserved BAG region that also binds the ATPase domain of HSP70
proteins to affect the rate of substrate binding and release 35. Conversely, Hop, carboxy
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terminus of HSP70-binding protein (CHIP) and immunophilins all bind both HSP70 and
HSP90 via tetra-tricopeptide repeat (TPR) domains, which allow the transfer of substrates
between them 8, 11. CHIP is critical to quality control processes and ubiquitinates misfolded
proteins when correct folding cannot be achieved (see Figure 1B) 36, 37, while
immunophilins are necessary for the functions of the p23 steroid aporeceptor-associated
protein 11. Lastly, prefoldin, also known as GimC, helps TriC/CCT-dependent folding of
tubulin and actin by way of its 6 tentacle-like processes that trap unfolded substrates and
assist with folding in collaboration with HSP70/HSP9038, 39.
The transcription factors HSF1 and HSF2 regulate chaperone and co-
chaperone expression in the cell
The number of misfolded proteins increases during times of cellular stress, including
oxidative stress and proteasome inhibition. Therefore, many chaperones are induced at the
transcriptional level in the presence of these conditions to protect against the toxicity of
misfolded proteins. There are at least 4 transcription factors (HSF1-4) that regulate heat
shock proteins. HSF1 is the primary transcription factor involved in this process and binds
heat shock response elements (HSE) in the promoter regions of stress-induced genes. HSF1
is found throughout the cytosol as a monomer that binds HSP90 to inhibit its chaperone
activity. During stress, denatured proteins competitively bind HSP90 40, effectively
releasing HSF1, thereby allowing it to translocate to the nucleus as trimers 41. In the
nucleus, increased HSF1 upregulates the expression of chaperones, including HSP70.
HSP70 then binds HSF1, which in turn, attenuates the HSF response, indicating a feedback
mechanism 42. Interestingly, part of the stress response induced by HSF1 includes the
upregulation of ubiquitin, suggesting that it regulates the ubiquitin proteasome system to
enhance the cell’s capacity to degrade proteins during stress (recently reviewed by Willis et
al.43). The roles of the remaining three HSFs in the stress response are less well studied.
Studies have shown that HSF2 contributes to the inducible expression of heat shock protein
genes by interacting with HSF1 44. The roles of HSF3 and HSF4 as factors that regulate the
expression of non-classical and sHSPs are just beginning to be understood 45, 46.
Cells have a diverse array of molecular chaperones available to them in the cytosol and
mitochondrial compartments that are regulated by the transcription factors NF-κB and
HSF1-4. While these chaperones primarily play a role in refolding proteins, some co-
chaperones cross talk with the ubiquitin proteasome system to directly ubiquitinate proteins
for subsequent degradation by the proteasome. While much of the work on molecular
chaperones has been in non-cardiovascular systems, their role in the heart during health and
disease is becoming more greatly appreciated.
Cardiac chaperones are regulated in the pathophysiology of a number of
common cardiac diseases
Cardiac hypertrophy
Cardiac chaperones such as HSP70, CryAB, and HSP22 (alphaC-crystallin) increase in
expression during the development of cardiac hypertrophy (Table 1). HSP70 can be induced
by a variety of hypertrophic stimuli, including aortic banding, angiotensin II infusion,
isoproterenol infusion and swimming 57. CryAB can be induced in rat cardiomyocytes in
response to endothelin-1 induced cardiomyocyte hypertrophy, resulting in a 2-fold increase
in CryAB expression. The DNA binding activity of HSF1 is heightened as a result of
increasing pre-load in heart 71. Since cardiac hypertrophy is a response to a number of stress
stimuli, this general increase in cardiac chaperone expression in cardiac hypertrophy is not
surprising. However, the purpose behind this increased chaperone expression is much less
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well understood. Mice with transgenic overexpression of CryAB gene challenged with 2
weeks of aortic banding to induce pathologic cardiac hypertrophy exhibit a significant
reduction in NFAT (nuclear factor of activated T cells) transactivation and attenuated
hypertrophy 86. This contrasts to CryAB null mice, which display an enhanced NFAT
transactivation at baseline, and an accelerated development of heart failure in response to
pressure overload induced by aortic banding 86. These studies demonstrate that cardiac
CryAB plays a role in suppressing cardiac hypertrophic response, possibly through
inhibiting NFAT signaling.
In contrast to CryAB’s ability to attenutae cardiac hypertrophy, HSP70 is necessary for the
induction of cardiac hypertrophy. One potential mechanism by which HSP70 may
accomplish this is through its association with the activated form of histone deacetylase2
(HDAC2). Overexpressing a dominant negative form of HSP70 or decreasing HDAC2 with
siRNA blunts the hypertrophic response in the heart. Furthermore, cardiac hypertrophy
induced by isoproterenol infusion or aortic banding in mice lacking HSP70, results in a
blunting of HDAC2 activity 57. This suggests a role for HSP70 in the induction of cardiac
hypertrophy, possibly through its stabilization of HDAC2. This HSP70-dependence of
HDAC2 activity is interesting because of the importance of HDAC2 in cardiac hypertrophy
signaling. The HDACs are instrumental in regulating hypertrophic gene expression in
pathological settings 49. Class II HDACs (HDAC 4, 6, 7, 9) negatively regulate hypertrophy
by repressing MEF/GATA/NFAT-mediated gene transcription 87. Conversely, the Class I
HDAC 2 has been implicated in having acetylase-dependent pro-hypertrophic activity,
possibly by releasing repression of IGF-1 signaling 49, 57, 88.
Another cardiac chaperone, HSP22, has also been shown to increase during the development
of cardiac hypertrophy. HSP22 has several names, the most common one used in the
literature is H11 kinase, but alphaC-crystallin is sometimes used and indicates its
relationship to other sHSPs (see recent review 89). Increasing HSP22 expression results in
the activation of signaling pathways involved in survival and cell growth, including the
PI3K/Akt pathway, AMPK, PKC epsilon, nitric oxide, and mTOR89. These signaling
pathways induce pre-conditioning, growth, and protection against apoptosis among other
cardioprotective pathways 89. Recently, studies have identified that HSP22 increases during
the development of cardiac hypertrophy in a variety of animal models. Inducing a slowly
progressive cardiac hypertrophy in puppies through use of aortic banding (that parallels the
gradual progression of human disease to a much greater extent than acute aortic banding
models), causes HSP22 to increase ~3 fold 59. Increasing HSP22 expression in cultured
cardiomyocytes and the intact mouse heart (~ 7 fold) results in the development of a
spontaneous hypertrophy, characterized by the re-expression of the fetal gene program 59,
90. This suggests that the many cardioprotective pathways HSP22 induces 89 may be
detrimental if expressed chronically.
Physiologic versus Pathologic Hypertrophy
The differences in the underlying signaling between physiologic and pathologic cardiac
hypertrophy is only superficially understood. Discovering these differences is critical to our
understanding of what makes patients undergoing pathologic hypertrophy so susceptible to
heart failure, whereas patients undergoing physiologic hypertrophy (for example through
exercise) are not. Pathologic cardiac hypertrophy is induced by persistent pressure or
volume overload as a result of hypertension or valvular heart disease. Physiologic
hypertrophy, on the other hand, is induced by exercise. Both stimuli result in increases in
cardiomyocyte size, however, pathologic hypertrophy is limited in its ability to maintain
cardiac function, eventually resulting in heart failure. In contrast, physiologic cardiac
hypertrophy maintains and improves function, as illustrated in athletes. The difference in
cellular signaling between these two processes has been of great interest to researchers. A
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number of recent studies have lead to the hypothesis that HSF1 may regulate some of the
differences in the development of physiologic and pathologic cardiac hypertrophy (recently
reviewed by Toko et al.91). This is based largely on gene expression studies which have
shown a differential expression of ~100 genes 92–95. Among these differentially expressed
genes are a number of HSF1-regulated genes such as HSP70 and HSP27 as well as increases
in HSF1 itself. HSF1 may be one of many differences regulating the differential signaling of
physiologic and pathologic cardiac hypertrophy.
Heart Failure
In order to protect cardiomyocytes from injury, heat shock proteins within the cell increase
in response to externally applied stressors, including oxidative stress and inflammation.
Beginning in the late 1990s, researchers have been investigating the expression of heat
shock proteins in the failing human heart (Table 1). To this end, investigators have
examined the expression of HSP90, HSP72, HSC70, HSP27, and HSP60 from dilated
cardiomyopathy (DCM) patients, ischemic cardiomyopathy patients, and normal controls 60.
HSP72, HSC70, and HSP90 are not significantly changed between the 3 groups 60. In
contrast, DCM patients exhibit a two-fold increase in HSP27 expression in the heart
compared to healthy control patients. This is in addition to a doubling of the HSP60 level,
which also occurs in the hearts from ischemic heart disease patients 60. The fact that HSP72
protein doesn’t increase in heart failure (even though it is cardioprotective 96), while levels
of the HSP60 protein are doubled 60, suggests that there is differential regulation between
HSP60 and either HSF1 or HSF-2-regulated heat shock proteins. Indeed, following
induction of heart failure by placement of a permanent high left anterior descending
coronary artery ligation in rats, no differences can be seen between HSF1 and HSF-2
activity as determined by EMSA 7. Additionally, HSP72 mRNA levels are not increased. In
contrast, HSP60 mRNA increases and appears to be due to increased binding of NF-κB to
both of the NF-κB binding elements in the HSP60 gene. Since HSP60 contains NF-κB
binding elements, but HSP72 does not 7, this may explain why HSP60, but not other heat
shock proteins, are increased during heart failure.
In more acute studies, where Wistar rats undergo a permanent left anterior descending
coronary ligation to induce heart failure, acute increases in HSP72 and HSP27 are seen,
whereas HSP60 expression remains unaffected 61. However, after 8 weeks, at which time
the development of heart failure is significant, a decrease in HSP72 and HSP27 expression is
observed, which appears to be somewhat contradictory when compared to the results seen in
human heart failure patients (see above). Induction of heart failure in these rats also results
in a parallel increase in cardiac HSP60 levels. Additional studies have determined that these
increases in HSP60 correlate with a decrease in mitochondrial oxygen consumption rate as
well as an increase in markers for reactive oxygen species (determined by thiobarbiturate
reacting substance Toga, 2007 62). The differences in HSP regulation found in these Wistar
rat studies compared to the studies in human disease may be due to the relatively acute
nature of these studies compared to human studies, or possibly a result of species and even
strain dependent effects.
HSP60 in heart failure
Although HSP60 is predominantly found in the mitochondria, approximately 15% of total
cellular HSP60 normally resides within the cytoplasm 29. However, in both DMC and
ischemic heart disease hearts the distribution of HSP60 changes, with cytosolic HSP60
translocating to the mitochondria 63. In other studies of heart failure using animal models
and human explanted failing hearts, HSP60 has been found localized to the plasma
membrane where it is detectable on the cell surface by both flow cytometry and confocal
microscopy. Interestingly, localization of HSP60 to the plasma membrane of a cell
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correlates with an increase in apoptosis of the affected cell, possibly due to the fact that the
cell surface HSP60 may be able to interact with other cells to trigger the innate immune
response, resulting in the release of proinflammatory cytokines such as TNF-α. This would
make HSP60 an early signal inducing myocyte loss and contributing to heart failure 56.
These few studies indicate a number of potentially conflicting data that might be due to
differences resulting from species or strain variations, or from experimental design.
Considerably more work is needed to delineate the regulation of HSP60 in heart failure.
HSP60’s involvement in heart failure is made even more complicated by the fact that it is
also released from the cells and can be found circulating in plasma during early in heart
failure 56. Circulating HSP60 has been hypothesized to play a role in atherosclerosis by
inducing inflammation and autoimmune mechanisms (see recent reviews97, 98). The
presence of HSP60 in the blood of normal patients was first described in 1999 99. Recent
studies have investigated the relationship between chronic heart failure severity and serum
HSP60 levels 64. In 112 patients with CHF and 62 control subjects, serum HSP60 levels
were higher in patients with CHF compared to controls 64. CHF patients with advancing
New York Heart Association functional classes had higher levels of HSP60 as well 64.
Likewise, patients with cardiac events during the average 569 days of follow up had higher
serum HSP60 levels compared to event-free patients 64. These findings demonstrate a
relationship between serum HSP60 levels, the severity of CHF, and a high risk for adverse
cardiac events in patients with heart failure. The role of circulating HSP60 in the underlying
pathophysiology of heart failure has not been delineated.
Cardiac Ischemic Injury
Most studies investigating heat shock proteins in cardiac ischemia/reperfusion injury have
reported on their cardioprotective effects. However, a few studies have concentrated on the
regulation of chaperone protein expression and activity during the course of ischemia/
reperfusion injury (Table 1). Reperfusion following 20 minutes of ischemia results in
increases to both HSP70 and HSP90 mRNA levels, with the increase in HSP70 being much
higher than that of HSP90 ( ~75 fold and HSP90 ~16 respectively) 65. This increase in
HSP70 and HSP90 expression is most likely due to a concurrent increase in the transcription
factor HSF1 (but not HSF2), which in turn appears to be driven by an accumulation of
reactive oxygen species during ischemia/reperfusion injury 72. In addition though, other
studies have identified that HSF1 activation can be modulated by ATP concentrations within
the cell. Moderate decreases in intracellular ATP correlate with HSF1 activation, while
severe ATP depletion results in an attenuated HSF1 response, which can subsequently be
rescued upon ATP restoration 73. Studies investigating differential expression of genes in a
pig model of ischemia/reperfusion injury reveal that HSP22 significantly increases ~ 3 fold
after 1 hour of reperfusion 67. HSP22 is also significantly increased in cases of human
hibernating myocardium and pig models of hibernating myocardium 68.
HSP70/HSP72—Both HSP70 and HSP72 have proven to be beneficial to the outcome of
cardiac ischemia/reperfusion injury. Knocking-down HSP72 expression in isolated feline
cardiomyocytes increases their susceptibility to cell death in response to hypoxia and
reoxygenation 100. In addition, increasing HSP72 in adult male rats by successive bouts of
endurance exercise improves the outcomes of ischemia/reperfusion injury, illustrated by a
decrease in cardiac infarct size as well as the amount of cardiac apoptosis in endurance-
trained rats compared to sedentary controls96. In the case of HSP70, adenovirus-mediated
gene transfer into rabbit hearts results in a reduction in injury after ischemia/reperfusion
injury 101. Furthermore, at least 4 studies have demonstrated that the transgenic
overexpression of HSP70 in the heart of mice significantly protects against ischemia/
reperfusion injury 102–105. Since all of these studies increase HSP70 prior to the ischemia/
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reperfusion insult, it is not clear what the clinical utility of increased HSP70 at
therapeutically plausible time points (after ischemia/reperfusion injury) would be.
Small heat shock proteins: HSP20, HSP22, HSP27, alphaB-crystallin (CryAB)
(Table 1)—Increasing the HSP20 expression in isolated cardiomyocytes improves their
function 106 and protects against apoptosis induced by beta-agonist stimulation 107. Cardiac-
specific overexpression of HSP20 in mouse models (~10 fold) protects against ischemia/
reperfusion injury. When HSP20 transgenic hearts are challenged with ischemia/reperfusion
injury ex vivo, they exhibit an improved contractile performance, a decrease in indices of
myocyte cell death, and a significant decrease in infarct size compared to wild type hearts
108. This protective effect of HSP20 appears to be due to HSP20’s role in activating
autophagy, a critical mechanism for dealing with ischemia/reperfusion injury 109.
Transgenic mice in which serine 16 on HSP20 is mutated such that it is nonphosphorylatable
are more susceptible to ischemia/reperfusion injury than wild-type mice, in part, due to the
inability of the mutant HSP20 to activate autophagic pathways 109. HSP20 can protect
against ischemia/reperfusion injury via other mechanisms also. HSP20 protects not only
against oxidative stress due to ischemia/reperfusion injury, but recent studies have also
found that it can protect against other injuries due to increased oxidative stress such as
doxorubicin therapy 110. Recent studies have demonstrated that HSP20 expression is
regulated, at least in part, by the mircoRNA miR-320. Down-regulation of miR-320 using an
antagomir has been shown to be cardioprotective in ischemia reperfusion, in part, by its up-
regulation of HSP2066. In the case of HSP22, transgenic mice that have increased
expression of HSP22 are protected against ischemia/reperfusion injury. After 45 minutes of
coronary artery occlusion and reperfusion, HSP22 transgenic mice have an 82% reduction in
infarct size compared to controls 90, with HSP22 transgenic hearts exhibiting significant
activation of a number of survival kinases, including Akt and AMPK to which HSP22 binds
directly 90. The cardioprotective effect of HSP22 appears to be mediated specifically
through BMP signaling via activation of the PI3K/Akt pathway111. The small heat shock
protein HSP27 has also been shown to protect against ischemia/reperfusion injury using dog
cardiomyocytes, with just minimal (2–3 fold) increases in expression 112.
Previously we described the protective nature of CryAB in inhibiting cardiac hypertrophy.
However, this small heat shock protein is also cardioprotective against ischemia/reperfusion
injury when its expression is increased prior to insult. Transgenic mice in which CryAB is
overexpressed, suffer less cardiac oxidative stress, decreased extent of infarction, and
attenuated apoptosis and necrosis when challenged with ischemia/reperfusion injury 113.
Likewise, mice lacking CryAB and HSP27, both of which are highly expressed in the heart,
subjected to ischemia/reperfusion challenge exhibit a nearly 2 fold decrease in contractility
recovery, with parallel increases in necrosis and apoptosis measures compared to controls
114. These studies indicate that, while CryAB and HSP27) are not necessary for cardiac
development (CryAB/HSP27 mice develop normally and have no discernable differences in
heart structure from wild type), they do play a key role in anti-oxidative mechanisms during
ischemia/reperfusion injury 114.
Heat shock factor proteins (HSF1)
As the heart senses stress, it induces heat shock proteins by a number of mechanisms.
Studies have identified that many of the heat shock proteins are regulated by the HSF family
of transcription factors (Table 1). In the context of cardiac ischemia/reperfusion, HSF1
expression can up-regulate heat shock protein expression to protect against subsequent
ischemia/reperfusion injury. Mice with cardiac overexpression of HSF1 challenged with
ischemia/reperfusion injury recover faster, have smaller infarct sizes and decreased
cardiomyocyte cell death compared to wild-type mice 115. In addition, Akt is enhanced
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while Jun N-terminal kinase and caspase 3 (apoptotic mediators) are less activated than wild
type mice 115.
The cardioprotective role of HSF1 has been studied by using experimental models known to
induce HSF1. Specifcially, cardiac HSF1 has been induced by whole body hyperthermia
(WBH) or by transgenic over-expression of CaMKII-delta B. Upon HSF1 induction, these
models were then challenged with ischemia/reperfusion injury. Preconditioning mice with
WBH for 48 hours, then subjecting the isolated hearts to 20 minutes of normothermic
ischemia and 30 minutes of reperfusion results in an increase in both HSF1 mRNA and
protein and overall cardioprotection 116 The increase in HSF1expression is directly related
to the cardioprotection as this effect is abolished with siRNA HSF1 116. Inhibiting HSF1
with siRNA in the face of WBH results in an inhibition of HSP32, HSP47, and HSP60 and
increased thermal intolerance, resulting in a higher mortality rate 116. The Ca2+/calmodulin-
dependent kinase (CaMK)II is also instrumental in protecting the heart against ischemia/
reperfusion injury. CaMKII is a multi-functional kinase that regulates Ca2+ handling and
regulates cell death in response to ischemia/reperfusion injury. Increasing CaMKII-deltaB
expression protects against oxidative stress, hypoxia and angiotensin II-induced apoptosis
117. Recent studies have determined that this cardioprotection is due, in part, to increasing
inducible HSP70 through phosphorylation of HSF1 117. These studies suggest that HSF1
may be a common mechanism by which cardiomyocytes induce a number of heat shock
proteins to protect against cardiac/ischemia reperfusion injury.
At least 13 chaperones and co-chaperones regulated by at leat 2 HSF transcription factors
have been described identified in the heart (Table 1). Quite predictably, of the proteins
identified, their expression increases in cardiac disease and is generally cardioprotective.
While most studies have focused on the regulation of these chaperones, co-chaperones, and
transcriptions factors in heart failure, a growing number of studies have demonstrated more
broadly their regulation in cardiac hypertrophy and ischemia reperfusion injury (Table 1).
This cardioprotection includes a host of mechanisms that regulate growth and inhibit
apoptosis through a variety of systems including the PI3K/Akt pathway, AMPK, PKC
epsilon, nitric oxide, and mTOR. Pharmacologic enhancement of these endogenous
cardioprotective mechanisms may prove to be simple yet effective strategies for reducing
the morbidity and mortality associated wth common cardiac diseases.
Co-chaperones in the heart: Chaperone assistants and Protein Triage
Co-chaperones have many functions in the heart including assisting chaperones with protein
folding and/or assisting with other functions, including targeting damaged proteins for
degradation by the ubiquitin proteasome system in a process called protein triage 118.
Increased co-chaperone expression in the heart has been found to be cardioprotective in
ischemia and necessary to regulate proteins involved in Long-QT syndrome. A number of
co-chaperones have been identified that control the activity of chaperones, including DnaJ,
BAGs, Hop, CHIP, Immunophilins, and Prefoldin (Figure 1). Of these 6 general types of co-
chaperones, only DnaJ, BAG-1, Hop and CHIP have been described in the heart, and our
understanding of their role is preliminary (Table 1).
Using a pig model of ischemia/reperfusion to identify genes participating in mechanisms of
cell survival, the Dna J-like co-chaperone (pDJA1) was identified by microarray using
subtractive hybridization 82. pDJA1 is restricted to cardiomyocytes and is not present in
skeletal muscle, liver, lung, kidney, aorta, stomach, or spleen 82. pDJA1 increases somewhat
during ischemia, but increases 4 fold following ischemia and is protective against
staurosporine-induced apoptosis in isolated rat cardiomyocytes 82. Since the identification of
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pDJA1 in 2003, little more has been reported on it despite its potential role in limiting
damage in the post-ischemic myocardium.
Studies on the role of BAG-1 in cardiac ischemia reperfusion injury have demonstrated the
ability of BAG-1 to inhibit apoptosis and induce autophagy in order to protect
cardiomyocytes. BAG-1 interacts with HSC70 and HSP70 and promotes cell survival by
coordinating the function of these chaperones with the degradation of proteins by the
proteasome. Both BAG-1 isoforms (BAG-1S and BAG-1L) are rapidly induced after
ischemia challenge in rat cardiomyocytes, with the increase in BAG-1 being sustained after
subsequent reperfusion 83. The interaction of BAG-1 with HSC70 increases after ischemia/
reperfusion injury 83, and increasing BAG-1S and BAG-1L in cardiomyocytes reduces
apoptosis after ischemia/reperfusion injury. When BAG-1S or BAG-1L are fused to a
nuclear localization sequence to force their nuclear localization, they fail to protect
cardiomyoctyes, similar to BAG-1 deletion mutants that are unable to bind HSC70/HSP70
83. BAG-1 deletion constructs missing the N-terminal ubiquitin-like domain, however, do
not affect the proteins ability to protect against ischemia/reperfusion injury 83. These studies
demonstrate a novel cardioprotective role for BAG-1, with a critical component related to its
interaction with HSC70/HSP70 and cytoplasmic localization. In addition, subsequent studies
have identified that autophagy plays an important role in the adaptation to ischemia-
reperfusion injury in association with BAG-1 84. BAG-1 associates with the autophagosomal
membrane protein LC3-II and may induce autophagy using HSC70 84, 119. Intracardial
injection of BAG-1 siRNA attenuates the induction of LC3-II and abolishes the
cardioprotection achieved by adaption 119. The BAG-3 isoform participates in the induction
of macroautophagy in association with HSP22 84, demonstrating how BAG family members
may shuttle damaged or oxidized proteins into the autophagy pathway to improve cell
survival84.
The co-chaperone CHIP (carboxy terminus of HSP70 interacting protein) is one protein that
plays a key role in both the folding system (as a co-chaperone regulating HSP70) and in the
UPS as a ubiquitin ligase. CHIP directs the degradation of aggregate prone proteins120, 121,
such as poly-glutamine proteins, which are prevalent in conformation diseases such as
Alzheimer or Huntington’s disease122–124. Although CHIP binds HSP70, it can also target it
for degradation in the absence of cargo, possibly as a feedback mechanism to adjust
chaperone levels needed for the number of misfolded proteins (Figure 1B) 50. Recent studies
have identified BAG-2, a specific inhibitor of CHIP-dependent ubiquitin ligase activity, as a
common component of CHIP holocomplexes in vivo 125. CHIP plays an important role in
the heart in response to ischemia/reperfusion injury. When CHIP −/− mice are challenged
with ischemia/reperfusion injury in vivo, the ratio of the infarct area to the area of risk is
50% greater than that found in sibling wild type mice 85. CHIP −/− hearts are more prone to
cell death indicating a critical role of CHIP in ischemia/reperfusion injury. These studies
parallel the role of BAG proteins described above, indicating a critical role of CHIP in
shuttling damaged and oxidized proteins into autophagic pathways after ischemia/
reperfusion injury. The specific role of CHIP in autophagy has yet to be reported.
Cardiomyocyte CHIP increases in response to high glucose and is responsible for the
degradation of the pro-hypertrophic transcription factor GATA4 81. The significance of
these findings in cardiac disease has yet to be reported.
The co-chaperone FKBP38 is an immunophilin-type small heat shock protein that has
recently been implicated in the maturation of HERG (human Ether-à-go-go Related Gene,
also known as KCNH2 in newer nomenclature)126. The HERG gene encodes the voltage-
dependent delayed rectifier potassium channel (IKR) and mutations in HERG are among the
most common underlying cause of hereditary Long QT syndrome. Recent studies have
utilized proteomic screens to identify that HSC70, HSP90, HDJ2 (HSP-organizing protein)
Willis and Patterson Page 9













and BAG-2 are differentially expressed in models of Long QT syndrome caused by
mutations in HERG 126. However, the most relevant findings of these studies are that the co-
chaperone FKBP38 immunoprecipitates and co-localizes with HERG 126. Additionally,
siRNA knock-down of FKBP38 causes a reduction in HERG trafficking and overexpression
of wild type FKBP38 partially rescues HERG trafficking in the presence of F805C disease-
causing KCNH2 mutation126. These studies suggest an important role for the co-chaperone
FKBP38 in rescuing mutations in KCNH2 that lead to the Long QT syndrome.
A picture of the heat shock protein system as a mediator of protein quality control is
emerging. Specific co-chaperones such as CHIP have the ability to ubiquitinate proteins that
the chaperone/co-chaperone complex is unable to refold (Figure 1B). The ubiquitination of
key structural proteins, such as sarcomere proteins and transcription factors are critical to the
long term health of the heart (see recent reviews43, 51, 127, 128). These co-chaperones
represent a system of triage whereby protein quality is maintained, and in the long run, the
health of the cardiomyocyte is maintained.
Future directions: The role of drug therapies in cardiac health and
pathophysiology
Drugs that induce heat shock proteins
A number of studies reviewed here have tested the hypothesis that increasing heat shock
proteins improves the outcome of cardiac diseases experimentally, particularly in the context
of ischemia/reperfusion injury. While these studies were primarily proof of concept that
increasing heat shock proteins were cardioprotective, it is interesting to note that the fold
increase in these proteins was as little as 2. From a clinical standpoint, there are several
drugs and herbal products that increase heat shock proteins that may be beneficial in the
treatment of cardiac diseases. However, their clinical utility has yet to be tested
experimentally in the context of their regulation of heat shock proteins.
Geranylgeranylacetone (GGA)
GGA is a cyclic polyisoprenoid gastric ulcer drug that protects the gastric mucosa by
inducing HSF1 and HSP70 mRNA 129. It has recently been shown experimentally to be
cardioprotective by inducing HSP72 130, 131. It has also been shown experimentally to
suppress poly-glutamine toxicity (see recent review 132).
Arimoclomol
Arimoclomol, developed by CytRx, is a small molecule that acts by inducing HSF1 resulting
in downstream increases of HSP70 and HSP90 133. Experimentally, arimoclomol increases
HSP70 and HSP90 approximately 5 fold in an experimental model of ALS 134.
Arimoclomol is currently in phase II/II clinical trials as a treatment for ALS.
Celastrol
Celastrol is a triterpenoid compound with a retinoid skeleton extracted from Tripterygium
wilfordii that is used in traditional Chinese medicine. It potently induces HSF1 and HSP70
expression, having both anti-oxidant and anti-inflammatory activities 135. Celastrol has been
shown to ameliorate the neurodegeneration of SOD1 mutant mice; however, it has not been
determined if this is through its anti-inflammatory effects and/or its affect on HSF1 and
HSP70 induction 136.
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In addition to their ability to decrease cholesterol synthesis via inhibition of HMG-CoA,
statins have been shown to have many additional activities, including modulation of the
immune system, reduction in apoptosis, and an affect on nitric oxide production 137–139.
Both simvastatin and lovastatin induce HSP27, but not HSP70 and HSP90 in an osteoblast-
like cell line 140. Simvastatin induces HSF1 in vascular endothelial cells, to induce nuclear
translocation and the transcription of HSP70 and HSP90 141. Simvastatin induces HSP27 in
axotomized retinal ganglion cells to enhance their survival after optic nerve transaction 142
Statins increase HSF1 and HSF-2 in retinal ganglion cells in vivo 143. Statins act to increase
HSFs, HSP70, HSP90, and sHSPs, possibly in a cell dependent manner. Their effect on
cardiac heat shock proteins has not been identified to date. With the discovery of statin’s
ability to induce heat shock proteins, studies have identified a decreased prevalence of
Alzheimer’s disease in patients taking statins 144, 145 and a decrease in neurofibrulary
tangles 145. These studies suggest that a several drugs, including the widely prescribed
statins, have the potential to be cardioprotective due to their ability to prime critical heat
shock proteins in the heart. The use of most of these drugs has yet to be determined in
human studies.
Conclusion
During the development of cardiac hypertrophy, heart failure, and ischemia/reperfusion
injury, there is a general increase in a number of chaperones, co-chaperones, and the
transcription factors that regulate them. In this review, we discuss the their uniformly
protective mechanisms and the possibility that therapeutic regulation may enhance both
acute and chronic health of the heart. With the recent discovery that increases in soluble pre-
amyloid oligomers play a significant role in cardiac disease and are able to induce
cardiomyopathy experimentally5, there is a need for a rational way to increase chaperone/co-
chaperone function to combat the accumulation of misfolded proteins. A number of drugs
with the potential to increase heat shock proteins are being developed for neurodegenerative
diseases caused by misfolded proteins (i.e. poly-glutamine diseases such as Huntington’s
disease). Given the parallel mechanisms found in cardiac diseases and the overwhelming
evidence that increasing chaperones/co-chaperones is cardioprotective against the most
common cardiac diseases, there may be future clinical applicability in cardiology of these
drugs.
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Non-standard abbreviations
BAG Bcl2-associated athanogene
CHIP carboxy terminus of HSP70-binding protein
CryAB alphaB-crystallin
ERAD endoplasmic reticulum-associated degradation
HDAC histone de-acetylase
HSC cognate of heat shock protein
HSF heat shock factor
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HSP heat shock protein
PAO preamyloid oligomers
PolyQ poly-glutamine
TRiC (TCP1-ring complex, or chaperonin containing TCP1 (CCT)
UPS Ubiquitin proteasome system
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Figure 1. The regulation of the protein quality control and chaperone systems in the heart that
protect against the toxicity of misfolded proteins
A. Both NF-kB and HSF transcription factors regulate the expression of key molecular
chaperones in the mitochondria and cytosol, respectively. Stress-activated HSF1 and HSF2
also increase the expression of co-chaperones and ubiquitin expression. B. The upregulation
of both chaperones and ubiquitin help maintain protein quality control by either refolding
(chaperone) the protein or ubiquitinating misfolded proteins (co-chaperone, e.g. CHIP). This
is a dynamic process particularly important during cardiac stress. Adapted from: Kubota
2009 6 and Wang et al. 7
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Table 1
A summary of the known regulation of chaperones, co-chaperones, and transcription
factors involved in the heat shock protein response in cardiac hypertrophy, heart failure,
and ischemia reperfusion injury
N.D.=not determined.
Example substrate recognition/Other Cardiac Hypertrophy Heart Failure Ischemia reperfusion injury
Chaperones


































HSP72 increased at 1 week
post-coronary artery
occlusion 61
3. CCT (TRiC) TRiC binds Actin 51 N.D. N.D. N.D.
4. Small HSPs
 -AlphaB-Crystallin (=HSPB5) AlphaB-Crystallin binds desmin 52 AlphaB-Crystallin




 -HSP20 (=HSPB6) HSP20 binds actin and alpha-actinin53 N.D. N.D. HSP20 increased in I/R,
regulated, in part by
miR-32066.
 -HSP22 (=HSPB8, H11
kinase, alphaC-Crystallin)
HSP22 binds lipid membranes 54 HSP22 expression
increases ~3 fold in
cardiac hypertrophy
induced in dogs by
aortic banding 59
N.D. HSP22 expression is
increased ~3 fold 1 hour after
reperfusion following
ischemia in a pig model 67
In human hibernating
myocardium and swine
model of is hibernating
myocardial, HSP22 increased
68
 -HSP27 (=HSPB1, HSPB2) HSP27 binds IκB 55 N.D. No change in
HSP27 expression
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 -HSP60 HSP60 binds Bax and Bak 56 HSP60 decreased 13














ligation in rats for
9–12 weeks); may









DCM and IHD 63
Serum HSP60
levels are associated






1. HSF1 HSF1 binds the heat shock elements












ligation in rats) 7
Rat cardiac ischemia-
reperfusion results in
increased HSF1 activity, but
not HSF2 65. HSF1
induction in ischemia
mediated by ROS and ATP
levels 72, 73
2. HSF2 HSF-2 binds the heat shock elements
of HSP90, HSP27, c-Fos69; interacts







ligation in rats) 7
Co-Chaperones
1. DnaJ DnaJ binds ribosome bound nascent
polypeptides 74
N.D. N.D. DnaJ-like pDJA1 increased 4
fold after reperfusion in a pig
model of I/R82
2. BAG-1 BAG-1 binds Bcl-2, Raf1 75 N.D. N.D. BAG-1 protects against I/R
injury 83, 84
3. Hop Hop binds HSP70, HSP90 76 N.D. N.D. N.D.
4. carboxyl terminus of HSP70-
interacting protein (CHIP)





N.D.?? CHIP protects against
ischemia reperfusion injury
85
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Example substrate recognition/Other Cardiac Hypertrophy Heart Failure Ischemia reperfusion injury
cardiomyocytes in
vitro 81
5. Immunophilins FKBP38 binds mTOR complex 78 N.D. N.D. N.D.
6. Prefoldin Prefoldin binds Nascent chain of actin
and tubulin Chaperonin 79, 80
N.D. N.D. N.D.
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